Means that affect bone structure and mineralization. Bisphosphonates.
Composition and form of release
Concentrated solution for infusion. The active ingredient is zolendronic acid. 5 ml of concentrate contains 4 mg of zoledronic anhydrous acid, 1 ml of concentrate contains 0.8 mg of zoledronic anhydrous acid.
The drug is made in vials, one in one carton.
Zolacid is intended to prevent the symptoms associated with bone destruction, such as compression of the spine, pathological fractures, complications after surgery, complications of radiation therapy or hypercalcemia caused by a malignant tumor. It is used in the treatment of patients who are in the late stages of malignant neoplasms.
Zolacid is used to treat hypercalcemia caused by the progression of a malignancy.
It should not be used in the treatment of patients with intolerance to zoledronic acid or other bisphosphonates. The drug is not intended for use in women during pregnancy and breastfeeding, as there is no reliable information on the safety of zoledronic acid for the development of the newborn or fetus.
Use during pregnancy and breastfeeding
Method of application and dose
Zolacid treatment can only be given by a doctor who has experience in the administration of bisphosphonates.
Before administration, 4 mg of concentrate should be diluted in 100 ml of 0.5% glucose solution or 0.9% sodium chloride solution. The prepared drug is administered by infusion for at least 15 minutes.
Zolacid should not be co-administered with intravenous solutions containing calcium or other divalent cations.
To prevent the development of symptoms of bone destruction in patients with late-stage malignancies, the patient should receive 4 mg of the drug, pre-diluted in 100 ml of glucose or sodium chloride, by infusion once every 3 or 4 weeks.
During treatment with Zolacid, patients should receive daily calcium supplements of 500 mg and 400 IU of vitamin D.
Administration of Zolacid in high doses may cause the development of renal failure, as well as changes in the electrolyte composition of blood serum. If a patient develops symptoms of hypocalcemia, intravenous calcium gluconate is indicated.
Zolacid treatment may cause the patient to develop anemia, thrombocytopenia, leukopenia, pancytopenia, headache, paresthesia, dizziness, tremor, somnolence, epileptic seizures, sleep disturbances, confusion, conjunctivitis, uveitis, diarrhea, epiphysis. allergic reactions, bone pain, myalgia, arthralgia, osteonecrosis of the external auditory canal, renal dysfunction, arrhythmia, peripheral edema and muscle cramps.
Conditions and terms of storage
Zolacid should be stored in the original packaging in places that are protected from light and out of reach of children, at a temperature not exceeding 30 degrees. Duration of storage of drug at observance of the basic conditions – 2 years.